Drug repositioning for Alzheimer's disease

Corbett, Anne, Pickett, James, Burns, Alistair, Corcoran, Jonathan, Dunnett, Stephen Bruce ORCID: https://orcid.org/0000-0003-1826-1578, Edison, Paul, Hagan, Jim J., Holmes, Clive, Jones, Emma, Katona, Cornelius, Kearns, Ian, Kehoe, Patrick, Mudher, Amrit, Passmore, Anthony, Shepherd, Nicola, Walsh, Frank and Ballard, Clive 2012. Drug repositioning for Alzheimer's disease. Nature Reviews Drug Discovery 11 (11) , pp. 833-846. 10.1038/nrd3869

Full text not available from this repository.

Abstract

Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. Given the recent failures of various novel disease-modifying therapies in clinical trials, a complementary strategy based on repositioning drugs that are approved for other indications could be attractive. Indeed, a substantial body of preclinical work indicates that several classes of such drugs have potentially beneficial effects on Alzheimer's-like brain pathology, and for some drugs the evidence is also supported by epidemiological data or preliminary clinical trials. Here, we present a formal consensus evaluation of these opportunities, based on a systematic review of published literature. We highlight several compounds for which sufficient evidence is available to encourage further investigation to clarify an optimal dose and consider progression to clinical trials in patients with Alzheimer's disease.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Subjects:	R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry R Medicine > RM Therapeutics. Pharmacology
Publisher:	Nature Publishing Group
ISSN:	1474-1776
Last Modified:	21 Oct 2022 10:54
URI:	https://orca.cardiff.ac.uk/id/eprint/41689

Citation Data

Cited 203 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item